Briacell Therapeutics - 30BCTXZPreferred / convertible
13F holders, Q3 2025 (September 30)3holders
0new positions
0sold out
$0.34avg. 13F price*
At the end of Q3 2025, 3 institutions reported holding Briacell Therapeutics - 30 (BCTXZ) in their 13F filings, unchanged from Q2 2025. 0 opened new positions and 0 sold out. The largest holders were Heights Capital Management, Inc. ($186K), Sabby Management, LLC ($125K) and UBS Group AG ($22).
- Company
- Briacell Therapeutics - 30
- CUSIP
- 107930117
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q2 2025 → Q3 2025: 232,761 shares sold, net −232,761 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| Heights Capital Management, Inc. | — | Reduce -1.3% | 544,698 | $186K |
| Sabby Management, LLC | — | Reduce -37.5% | 374,488 | $125K |
| UBS Group AG | — | Reduce -94.5% | 66 | $22 |
"% of holder's portfolio" is BCTXZ's weight in each manager's 13F, not the share of Briacell Therapeutics - 30 the manager owns.